

# Lightbridge Provides Year-End Business Update and Outlines Upcoming Milestones for Enfission Joint Venture

Reports current cash balance of approximately \$27 million to accelerate commercialization efforts and fund R&D activities well into 2019

RESTON, Va., March 15, 2018 (GLOBE NEWSWIRE) -- **Lightbridge Corporation** (NASDAQ:LTBR), a nuclear fuel technology company, today provided a business update, including upcoming milestones for Enfission LLC, its joint venture with Framatome, Inc., a leader in designing, building, servicing, and fueling today's reactor fleet and advancing nuclear energy. The Company also reported financial results for the year ended December 31, 2017.

Seth Grae, President & Chief Executive Officer of Lightbridge Corporation, commented, "In 2017 we laid the foundation for what would become the most pivotal event in our corporate history. In January of this year we announced the launch of Enfission, our 50-50 joint venture with Framatome, to develop, license and sell nuclear fuel assemblies based on Lightbridge-designed metallic fuel technology and other advanced nuclear fuel intellectual property. I am pleased to report that with Framatome we are making rapid progress since the formation of Enfission. Specifically, we are working on developing a regulatory licensing plan for lead test assemblies and we expect to present this plan to the U.S. Nuclear Regulatory Commission (NRC) later this year. We are also developing analytical models for our metallic fuel technology that can be used for reactor analysis and regulatory licensing. Our goal is to commence metallic fuel sample fabrication for irradiation in a test reactor in 2020. We continue to receive valuable feedback on our fuel technology development plan through our Nuclear Utility Fuel Advisory Board, which is comprised of four leading U.S. nuclear utilities. We expect Enfission to enter into a lead test rod and/or lead test assembly agreement with at least one of these four companies in 2019-2020, which could result in our first fuel-related cash contributions from a utility customer."

"We continue to expand our intellectual property protection. In January, we received a Notice of Allowance in the U.S. that extends Lightbridge's patent portfolio coverage to an entire metallic fuel assembly design for Western-type pressurized water reactors, which comprise two-thirds all power reactors in operation worldwide. Our metallic fuel designs can also be adapted for use in nearly all other power reactors around the world. We were also awarded key patents in Europe and China related to our innovative metallic fuel design, which extend through 2034. With dozens of patents issued and pending around the world, we have assembled a strong intellectual property portfolio that, through Enfission, we plan to leverage into commercial arrangements."

"There is growing governmental support for nuclear energy in the U.S. and around the

world. Nearly all the nuclear power plants in the U.S. have received license renewals to allow operations to 60 years, and the first applicants for subsequent license renewals to extend reactor operations to 80 years have announced plans to begin the process with the NRC this year. Importantly, the White House has placed nuclear energy at the forefront of its energy agenda, including new programs to boost nuclear power research and development. Importantly, our nuclear fuel designs are attracting attention at both the commercial and governmental levels, given that our technology holds significant promise to enhance reactor safety, improve nuclear power plants' economics through increased power output and longer fuel cycles, improve proliferation resistance of spent fuel so bombs can't be made from nuclear waste, and reduce the amount of waste per unit of electricity generated."

"Since the end of 2017, we have significantly enhanced our balance sheet, including a recent capital raise with European family offices, strategic and accredited American and European investors. As a result, our balance sheet is stronger than any time in our corporate history and we now have approximately \$27 million of cash on hand as of today, which we expect will help significantly accelerate our commercial efforts."

#### **Balance Sheet Overview**

At December 31, 2017, we had cash and cash equivalents of approximately \$4.5 million, as compared to approximately \$3.6 million at December 31, 2016. The \$0.9 million increase in cash and cash equivalents resulted from the sale of approximately \$6.0 million of common stock during the twelve months ended December 31, 2017, partially offset by net cash used in operating activities of approximately \$5.0 million and cash used in investing activities of approximately \$0.2 million. The Company used cash during the 12 months ended December 31, 2017 primarily to fund general and administrative expenses and for research and development. The Company had approximately \$3.6 million in working capital at December 31, 2017 as compared to working capital of approximately \$3.4 million at December 31, 2016. Stockholders' equity at December 31, 2017 was approximately \$5.8 million compared to stockholders' equity of approximately \$5.6 million at December 31, 2016.

#### Operating Results – Year End of Fiscal 2017 Compared to Year End of Fiscal 2016

For the year ended December 31, 2017, Lightbridge's net loss available to common shareholders was approximately \$7.4 million, or a loss of \$0.71 per share, on revenue of \$0.2 million. Lightbridge focused its efforts on forming the joint venture with Framatome, which included Framatome's due diligence work on our nuclear fuel before entering into the Enfission joint venture. In the same period of 2016, the net loss available to common shareholders was \$7 million, or loss per share of \$1.48 per share, on revenue of \$0.8 million. All revenue was generated from consulting services. Stock-based compensation expense was \$1.2 million for the year ended December 31, 2017 compared to \$2.0 million for the year ended December 31, 2016. For the year ended December 31, 2017, the Company's cash flows used in operating activities were \$5.0 million versus \$6.0 million used in operating activities for the same period of 2016. The decrease in cash used in operating activities in 2017 of \$1.0 million was primarily due to the decrease in revenue and operating expenses and the change in working capital items.

#### 2017 Year End Conference Call

Lightbridge will host a conference call on Friday, March 16th at 10:00 a.m. US Eastern Time to discuss the company's financial results for the year ending December 31, 2017, as well as

the Company's corporate progress and other meaningful developments.

Interested parties can access the conference call by calling 877-407-0778 for U.S. callers, or +1- 201-689-8565 for international callers. The call will be available on the Company's website via webcast at http://ir.ltbridge.com/events.cfm. The conference call will be led by Seth Grae, President and Chief Executive Officer and other Lightbridge executives will also be available to answer questions. Questions may also be submitted in writing before or during the conference call to ir@Ltbridge.com.

A webcast will also be archived on the Company's website and a telephone replay of the call will be available approximately one hour following the call, through midnight April 16, 2018, and can be accessed by calling: 877-481-4010 (U.S. callers) or +1- 919-882-2331 (international callers) and entering conference ID: 26581.

#### **About Lightbridge Corporation**

Lightbridge (NASDAQ:LTBR) is a nuclear fuel technology development company based in Reston, Virginia, USA. The Company develops proprietary next generation nuclear fuel technologies for current and future reactors, which significantly enhances the economics and safety of nuclear power, operating about 1000° C cooler than standard fuel. In January 2018, Lightbridge and Framatome, Inc. formed a 50-50 joint venture, Enfission, LLC, to develop, license, manufacture, and sell nuclear fuel assemblies based on Lightbridge-designed metallic fuel technology and other advanced nuclear fuel intellectual property. Enfission has the exclusive rights to this technology and is responsible for the development of manufacturing processes and fuel assembly designs for pressurized water reactors (PWRs), boiling water reactors (BWRs), water-cooled small modular reactors, and water-cooled research reactors developed around this intellectual property. PWRs and BWRs constitute the most widely used reactor types in the world. Four large electric utilities that generate about half the nuclear power in the US already advise Lightbridge on fuel development and deployment. In addition to distributions from Enfission based on the parties' ownership interest in the joint venture, Lightbridge anticipates receiving future licensing revenues in connection with sales by Enfission of nuclear fuel incorporating its intellectual property. Lightbridge also provides comprehensive advisory services for established and emerging nuclear programs based on a philosophy of transparency, non-proliferation, safety and operational excellence. For more information please visit: www.ltbridge.com.

To receive Lightbridge Corporation updates via e-mail, subscribe at http://ir.ltbridge.com/alerts.cfm.

Lightbridge is on Twitter. Sign up to follow @LightbridgeCorp at http://twitter.com/lightbridgecorp.

#### Forward Looking Statements

With the exception of historical matters, the matters discussed in this news release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the timing, progress and potential challenges relating to Enfission's anticipated operations and other developments, the expected timing and results arising from research and development with respect to Enfission, the possibility of obtaining the Company's first fuel-related contributions from a utility customer, the

expected market for and the position of the Company's product and service offerings, and the impact of governmental support for nuclear energy initiatives.

These statements are based on current expectations on the date of this news release and involve a number of risks and uncertainties that may cause actual results to differ significantly from such estimates. The risks include, but are not limited to, the degree of market adoption of the Company's product and service offerings; market competition; the success of our Enfission joint venture with Framatome; dependence on strategic partners; demand for fuel for nuclear reactors; the Company's ability to manage its business effectively in a rapidly evolving market; as well as other factors described in Lightbridge's filings with the Securities and Exchange Commission. Lightbridge does not assume any obligation to update or revise any such forward-looking statements, whether as the result of new developments or otherwise. Readers are cautioned not to put undue reliance on forward-looking statements.

#### **Investor Relations Contact:**

David Waldman/Natalya Rudman Tel. +1 855-379-9900 ir@Ltbridge.com

\*\*\* tables follow \*\*\*

### Lightbridge Corporation Consolidated Balance Sheets

	December 31, 2017		December 31, 2016	
ASSETS				
Current Assets				
Cash and cash equivalents	\$	4,515,398	\$	3,584,877
Restricted cash		-		114,012
Accounts receivable - project revenue and reimbursable project		10,400		388,434
Prepaid expenses and other current assets		70,067		80,933
Deferred financing costs, net		491,168		491,168
Total Current Assets		5,087,033		4,659,424
Other Assets				
Patent costs		1,367,692		1,160,465
Deferred financing costs, net		491,268		982,486
Total Other Assets	-	1,858,960	-	2,142,951
Total Assets	\$	6,945,993	\$	6,802,375
LIABILITIES AND STOCKHOLDERS' EQUITY				
Current Liabilities				
Accounts payable and accrued liabilities	\$	1,151,210	\$	1,216,321
Total Current Liabilities		1,151,210		1,216,321
Long-Term Liabilities				
Deferred lease abandonment liability		-		28,464
Total Liabilities		1,151,210		1,244,785

Commitments and contingencies - Note 7

Stockholders' Equity

Convertible Preferred stock, \$0.001 par value, 10,000,000 authorized shares, convertible		
Series A		
preferred shares, 1,020,000 shares issued and outstanding at December 31, 2017 and		
December 31, 2016	1,020	1,020
Common stock, \$0.001 par value, 100,000,000 authorized shares, 12,737,703 shares and		
7,112,143		
shares issued and outstanding as of December 31, 2017 and 2016, respectively	12,738	7,112
Additional paid-in capital	93,602,539	86,266,075
Accumulated Deficit	(87,821,514)	(80,716,617)
Total Stockholders' Equity	5,794,783	5,557,590
Total Liabilities and Stockholders' Equity	\$ 6,945,993	\$ 6,802,375

## Lightbridge Corporation Consolidated Statements of Operations

	Years Ended December 31,		
	2017	2016	
Revenue:			
Consulting Revenue	\$ 175,446	\$ 760,577	
Cost of Consulting Services Provided	107,091	456,565	
Gross Margin	68,355	304,012	
Operating Expenses General and administrative Research and development expenses Total Operating Expenses	4,383,066 2,282,938 6,666,004	5,190,549 2,748,337 7,938,886	
Operating Loss	(6,597,649		
Other Income and (Expenses) Warrant revaluation Warrant modification expense Interest income Financing costs Interest expense Total Other Income and (Expenses)	- - 65 (491,218 (16,095 (507,248	(29,448)	
Net loss before income taxes	(7,104,897	) (6,345,176)	
Income taxes		<u>-</u>	
Net loss	(7,104,897	) \$ (6,345,176 )	
Accumulated preferred stock dividend	(276,578	) (80,578)	
Deemed dividend on convertible preferred stock dividend conversion due to beneficial feature		(581,300)	
Net loss attributable to common shareholders	\$ (7,381,475	) \$ (7,007,054)	
Net Loss Per Common Share, Basic and Diluted	\$ (0.71	) \$ (1.48)	

#### Lightbridge Corporation **Consolidated Statements of Cash Flows**

Operating Activities:         2016         2016           Net Loss         \$ (7,104,897 )         \$ (6,345,176)           Adjustments for reconcile net loss from operations to net cash used in operating activities:         \$ (7,104,897 )         \$ (6,345,176)           Stock-based compensation         1,193,306         1,984,011           Amortization of deferred financing costs         491,218         1,984,011           Abandonment loss         377,800         21,825           Warrant revaluation         16,055         26,853           Warrant modification expense         16,055         26,853           Unpiled interest expense on deferred lease abandonment liability         16,055         26,853           Unpiled interest expense on deferred lease abandonment liability         10,866         376,034         2248,637           Cocounts payable and accrued liabilities         378,034         1248,637         10,966         370,006           Prepaid expenses and other assets         10,966         370,006         10,906         10,906           Net Cash Used In Operating Activities         207,227         (209,871         10,906         10,906         10,906         10,906         10,906         10,906         10,906         10,906         10,906         10,906         10,906         10,906		Years Ended December 31,		
Net Loss         \$ (7,104,897 )         \$ (6,345,176)           Adjustments to reconcile net loss from operations to net cash used in operating activities:         1,193,306         1,984,011           Stock-based compensation         1,193,306         1,984,011           Amortization of deferred financing costs         3,780         1.25,257           Warrant modification expense         3,780         1,62,257           Warrant modification expense         1,60,95         26,953           Implied interest expense on deferred lease abandonment liability         16,095         26,953           Charges in operating working capital items         378,034         (248,637)           Cocounts receivable - fees and reimbursable project costs         378,034         (248,637)           Crocumts receivable - fees and reimbursable project costs         378,034         (248,637)           Prepaid expenses and other assets         10,866         37,096           Accounts payable and accruel diabilities         159,953         101,960           Deferred lease abandonment liability         (185,683)         (269,706           Net Cash Used In Operating Activities         207,227         (209,871           Investing Activities         207,227         (209,871           Pate proceeds from the issuance of common stock         6,027,064				
Slock-based compensation         1,193,306         1,984,011           Amortization of deferred financing costs         491,218         191,345           Warrant revaluation         - (162,398)         1,600,500           Warrant revaluation         16,000         26,953           Warrant revaluation         16,000         26,953           Warrant modification expense         16,000         26,953           Implied interest expense on deferred lease abandonment liability         16,000         26,953           Changes in operating working capital lems:         378,034         (248,637)           Accounts receivable - fees and reimbursable project costs         378,034         (248,637)           Prepaid expenses and other assets         10,866         87,096           Accounts pracipable and accrued liabilities         159,595         101,960           Deferred lease abandonment liability         (185,683)         (260,207)           Net Cash Used In Operating Activities         2(207,227)         (209,871)           Net Cash Used In Investing Activities         2(207,227)         (209,871)           Net Cash Used In Investing Activities         8(207,227)         (209,871)           Net proceeds from the issuance of preferred stock         6,027,064         6,135,804           Net proceeds from th	Net Loss	<del></del>		
Amortization of deferred financing costs         491,218         191,345           Abandonment loss         37,780         -           Warrant revaluation         -         (1,672,573)           Warrant modification expense         162,398           Implied interest expense on deferred lease abandonment liability         16,095         28,085           Changes in operating working capital items:         378,034         (248,637)           Prepaid expenses and other assets         10,066         87,099           Accounts receivable - fees and reimbursable project costs         378,034         (248,637)           Prepaid expenses and other assets         10,066         87,099           Accounts payable and accrued liabilities         159,953         101,960           Deferred lease abandonment liability         (168,683)         (263,437)           Net Cash Used in Operating Activities         (207,227)         (209,871)           Investing Activities:         (207,227)         (209,871)           Patent costs         (207,227)         (209,871)           Net Cash Used in Investing Activities         6,027,064         6,135,804           Net Cash Used In Investing Activities         6,027,064         6,135,804           Net proceeds from the issuance of preferred stock         6,027,064	•	1 103 306 1 084 011		
Abandomment loss         37,760         (1,672,53           Warrant revaluation         1 (1,672,53           Warrant modification expense         1 (6,72,53           Implied interest expense on deferred lease abandomment liability         1 (6,92,53           Changes in operating working capital items:         378,034         (248,637           Prepaid expenses and other assets         10,866         87,096           Deferred lease abandomment liability         (185,683)         10,866           Accounts payable and accrued liabilities         (50,03,328)         (50,60,600)           Deferred lease abandomment liability         (185,683)         (263,437           Net Cash Used In Operating Activities         207,227         (209,871           Net Cash Used In Investing Activities         207,227         (209,871           Net Cash Used In Investing Activities         6,027,024         2,800,000           Net proceeds from the issuance of common stock         6,027,064         6,135,000           Net proceeds from the issuance of note payable         6,027,064         135,000           Respayment of note payable         6,141,076         9,147,620           Net Cash Provided by Financing Activities         930,521         2,961,690           Cash and Cash Equivalents, Beginning of Year         3,584,877	·			
Warrant revaluation         -         (16,72,673)           Warrant modification expense         16,23,981           Implied interest expense on deferred lease abandonment liability         16,095         26,955           Changes in operating working capital items:         378,034         (248,637           Prepaid expenses and other assets         10,666         87,096           Accounts payable and accrued liabilities         159,953         101,960           Deferred lease abandonment liability         (185,683)         (263,437)           Net Cash Used in Operating Activities         (207,227)         (209,871)           Patent costs         (207,227)         (209,871)           Net Cash Used in Investing Activities         (207,227)         (209,871)           Net Cash Used In Investing Activities         (207,227)         (209,871)           Net proceeds from the issuance of common stock         6,027,064         6,135,804           Net proceeds from the issuance of note payable         6,027,064         6,135,804           Net proceeds from the issuance of note payable         9,000         1,000           Repayment of note payable         9,140,602         1,114,012         2,961,603           Net Cash Provided by Financing Activities         9,147,602         6,31,804         6,31,804 <t< td=""><td></td><td></td></t<>				
Warrant modification expense         162,388           Implied interest expense on deferred lease abandonment liability         16,095         26,958           Changes in operating working capital items:         378,034         (248,637           Accounts receivable - fees and reimbursable project costs         378,034         (248,637           Prepaid expenses and other assets         159,953         101,960           Accounts payable and accrued liabilities         159,953         101,960           Net Cash Used In Operating Activities         (50,003,328)         (50,606)           Investing Activities:         207,227         (209,871           Patent costs         207,227         (209,871           Net Cash Used In Investing Activities         207,227         (209,871           Financing Activities:         207,227         (209,871           Net proceeds from the issuance of common stock         6,027,064         6,135,804           Net proceeds from the issuance of note payable         6,027,064         6,135,804           Net proceeds from the issuance of note payable         9,141,602         2,180,000           Restricted cash         114,012         211,820           Net Cash Provided by Financing Activities         3,93,64,87         6,21,80           Cash and Cash Equivalents, Beginning of Year		•		
Implied interest expense on deferred lease abandonment liability         16,055         26,935           Changes in operating working capital items:         378,034         (248,637)           Prepaid expenses and other assets         10,866         87,096           Accounts payable and accrued liabilities         10,866         87,096           Accounts payable and accrued liabilities         (185,693)         101,960           Deferred lease abandonment liability         (185,693)         (269,437)           Net Cash Used in Operating Activities         (207,227)         (209,871)           Patent costs         (207,227)         (209,871)           Net Cash Used in Investing Activities         (207,227)         (209,871)           Prepared Stock from the issuance of common stock         6,027,064         6,135,804           Net proceeds from the issuance of preferred stock         6,027,064         6,135,804           Net proceeds from the issuance of note payable         1         (35,000)           Repayment of note payable         1         (35,000)           Repayment of note payable         6,141,076         9,147,624           Net Loash Provided by Financing Activities         930,521         2,961,693           Cash and Cash Equivalents, Beginning of Year         3,584,877         623,184		•		
Changes in operating working capital items:         2(248,637)           Accounts receivable - fees and reimbursable project costs         378,034         (248,637)           Prepaid expenses and other assets         10,866         87,096           Accounts payable and accrued liabilities         159,953         101,960           Deferred lease abandonment liability         (80,003,328)         (263,437)           Net Cash Used in Operating Activities         (207,227)         (209,871)           Patent costs         (207,227)         (209,871)           Net Cash Used in Investing Activities         (207,227)         (209,871)           Financing Activities:         (207,227)         (209,871)           Net proceeds from the issuance of common stock         6,027,064         6,135,804           Net proceeds from the issuance of preferred stock         6,027,064         6,135,804           Net proceeds from the issuance of preferred stock         6,027,064         6,135,804           Net proceeds from the issuance of preferred stock         6,027,064         6,135,804           Net proceeds from the issuance of preferred stock         6,027,064         6,135,804           Repayment of note payable         6,027,064         6,135,804           Net proceeds from the issuance of preferred stock         9,025         2,961,693     <		•		
Accounts receivable - fees and reimbursable project costs         378,034         (248,637)           Prepaid expenses and other assets         10,866         870,906           Accounts payable and accrued liabilities         119,965         101,960           Deferred lease abandonment liability         (185,683)         (263,437)           Net Cash Used In Operating Activities         \$ (5,903,328)         (5,976,000)           Investing Activities:         \$ (207,227)         (209,871)           Patent costs         \$ (207,227)         (209,871)           Net Cash Used In Investing Activities         \$ (207,227)         (209,871)           Financing Activities:         \$ (207,227)         (209,871)           Net proceeds from the issuance of common stock         \$ (6,27,064)         6,135,804           Net proceeds from the issuance of preferred stock         \$ (2,900,000)         6,135,800           Propayment of note payable         \$ (3,500)         1,140,000         2,280,000           Repayment of note payable         \$ (135,000)         1,140,000         2,145,000         1,245,000           Restricted cash         \$ (14,1076)         9,147,624         1,245,000         1,245,000         1,245,000         1,245,000         1,245,000         1,245,000         1,245,000         1,245,000         1,		.,		
Prepaid expenses and other assets         10,866         87,096           Accounts payable and accrued liabilities         159,953         101,960           Deferred lease abandonment liability         (185,683)         (263,437           Net Cash Used In Operating Activities         (5,003,328)         (5,976,006)           Investing Activities:         Very Comment of Section of Se		378,034 (248,637		
Accounts payable and accrued liabilities         159,953         101,960           Deferred lease abandonment liability         (185,683)         (263,437)           Net Cash Used In Operating Activities         (5,003,328)         (5,976,606)           Investing Activities:         207,227         (209,871)           Patent costs         (207,227)         (209,871)           Net Cash Used In Investing Activities         (207,227)         (209,871)           Financing Activities:         8         (207,227)         (209,871)           Net proceeds from the issuance of common stock         6,027,064         6,135,804           Net proceeds from the issuance of preferred stock         6,027,064         6,135,804           Net proceeds from the issuance of note payable         -         135,000           Repayment of note payable         -         135,000           Restricted cash         114,012         21,820           Net Cash Provided by Financing Activities         6,141,076         9,147,624           Net Increase In Cash and Cash Equivalents         930,521         2,961,693           Cash and Cash Equivalents, Reginning of Year         3,584,877         623,184           Cash and Cash Equivalents, End of Year         \$ 4,515,398         \$ 3,584,877           Interest				
Net Cash Used In Operating Activities:         (5,003,328)         (5,976,060)           Investing Activities:         (207,227)         (209,871)           Patent costs         (207,227)         (209,871)           Net Cash Used In Investing Activities         (207,227)         (209,871)           Financing Activities:         State of Cash (207,024)         6,135,804           Net proceeds from the issuance of preferred stock         6,027,064         6,135,804           Net proceeds from the issuance of note payable         6         135,000           Repayment of note payable         6         (135,000)           Repayment of note payable         114,012         211,820           Net Cash Provided by Financing Activities         6,141,076         9,147,624           Net Increase In Cash and Cash Equivalents         930,521         2,961,693           Cash and Cash Equivalents, Beginning of Year         3,584,877         623,184           Supplemental Disclosure of Cash Flow Information:         2         2           Cash and Cash Equivalents, End of Year         \$ 2,83         3,584,877           Increes         \$ 2, 6         \$ 2,433           Increes         \$ 2, 6         \$ 2,433           Increes         \$ 2, 6         \$ 2,433           Increes <td></td> <td>159,953 101,960</td>		159,953 101,960		
Investing Activities:   Patent costs	Deferred lease abandonment liability	(185,683 ) (263,437		
Patent costs         (207,227 )         (209,871 )           Net Cash Used In Investing Activities         (207,227 )         (209,871 )           Financing Activities:         State of Cash Used In Investing Activities:         50,27,064 (20,800 )         6,135,804 (20,800 )           Net proceeds from the issuance of preferred stock         6,027,064 (20,800 )         2,800,000 )         6,2800,000 (20,800 )         6,135,000 (20,800 )         6,135,000 (20,800 )         6,145,000 (20,800 )         6,145,000 (20,800 )         6,145,000 (20,800 )         6,145,000 (20,800 )         6,141,000 (20,800 )         6,141,000 (20,800 )         6,141,000 (20,800 )         6,141,000 (20,800 )         6,141,000 (20,800 )         6,141,000 (20,800 )         6,141,000 (20,800 )         6,141,000 (20,800 )         6,141,000 (20,800 )         6,141,000 (20,800 )         6,141,000 (20,800 )         6,141,000 (20,800 )         6,141,000 (20,800 )         6,141,000 (20,800 )         6,141,000 (20,800 )         6,141,000 (20,800 )         6,141,000 (20,800 )         6,23,184 (20,800 )         6,23,184 (20,800 )         6,23,184 (20,800 )         6,23,184 (20,800 )         6,23,184 (20,800 )         6,23,184 (20,800 )         6,23,184 (20,800 )         6,23,184 (20,800 )         6,23,184 (20,800 )         6,23,184 (20,800 )         6,23,184 (20,800 )         6,23,184 (20,800 )         6,23,184 (20,800 )         6,23,184 (20,800 )         6,23,184 (20,800 )         6,23,184 (20,800 )         <	Net Cash Used In Operating Activities	(5,003,328 ) (5,976,060		
Net proceeds from the issuance of common stock         6,027,064         6,135,804           Net proceeds from the issuance of preferred stock         -         2,800,000           Proceeds from the issuance of note payable         -         135,000           Repayment of note payable         -         (135,000           Repayment of note payable         -         114,012         211,820           Net Cash Provided by Financing Activities         6,141,076         9,147,624           Net Increase In Cash and Cash Equivalents         930,521         2,961,693           Cash and Cash Equivalents, Beginning of Year         3,584,877         623,184           Cash and Cash Equivalents, End of Year         \$ 4,515,398         \$ 3,584,877           Supplemental Disclosure of Cash Flow Information:         S 2         \$ 2,433           Increst         \$ 2         \$ 2,433           Income taxes         \$ 2         \$ 2,433           Non-Cash Financing Activities:         \$ 2         \$ 1,664,999           Warrant liability – reclassification to equity         \$ 3         \$ 817,020           Deemed dividend on convertible preferred stock due to beneficial conversion feature         \$ 5         \$ 811,002           Accumulated preferred stock dividend         \$ 276,578         \$ 80,578	Patent costs			
Net proceeds from the issuance of preferred stock         -         2,800,000           Proceeds from the issuance of note payable         -         135,000           Repayment of note payable         -         (135,000)           Restricted cash         114,012         211,820           Net Cash Provided by Financing Activities         6,141,076         9,147,624           Net Increase In Cash and Cash Equivalents         930,521         2,961,693           Cash and Cash Equivalents, Beginning of Year         3,584,877         623,184           Cash and Cash Equivalents, End of Year         \$ 4,515,398         \$ 3,584,877           Supplemental Disclosure of Cash Flow Information:         S 2,433         \$ 2,433           Increest         \$ 5         \$ 2,433           Income taxes         \$ 5         \$ 2,433           Varrant liability – reclassification to equity         \$ 5         \$ 817,020           Deemed dividend on convertible preferred stock due to beneficial conversion feature         \$ 5         \$ 581,300           Accumulated preferred stock dividend         \$ 276,578         \$ 80,578	•	0.007.004		
Proceeds from the issuance of note payable         -         135,000           Repayment of note payable         -         (135,000)           Restricted cash         114,012         211,820           Net Cash Provided by Financing Activities         6,141,076         9,147,624           Net Increase In Cash and Cash Equivalents         930,521         2,961,693           Cash and Cash Equivalents, Beginning of Year         3,584,877         623,184           Cash and Cash Equivalents, End of Year         \$ 4,515,398         \$ 3,584,877           Supplemental Disclosure of Cash Flow Information:         Cash paid during the year:           Interest         \$ -         \$ 2,433           Income taxes         \$ -         \$ 2,433           Non-Cash Financing Activities:         \$ -         \$ 1,664,999           Warrant liability – reclassification to equity         \$ -         \$ 817,020           Deemed dividend on convertible preferred stock due to beneficial conversion feature         \$ -         \$ 581,300           Accumulated preferred stock dividend         \$ 276,578         \$ 80,578				
Repayment of note payable         (135,000)           Restricted cash         114,012         211,820           Net Cash Provided by Financing Activities         6,141,076         9,147,624           Net Increase In Cash and Cash Equivalents         930,521         2,961,693           Cash and Cash Equivalents, Beginning of Year         3,584,877         623,184           Cash and Cash Equivalents, End of Year         \$4,515,398         \$3,584,877           Supplemental Disclosure of Cash Flow Information:         Supplemental Disclosure of Cash Flow Information:         Supplemental Disclosure of Cash Flow Information:           Cash paid during the year:         Interest         \$ 2,433           Income taxes         \$ 2,433           Non-Cash Financing Activities:         \$ 2,433           Deferred financing costs         \$ 3,584,877           Parant liability – reclassification to equity         \$ 3,584,877           Deemed dividend on convertible preferred stock due to beneficial conversion feature         \$ 3,584,877           Accumulated preferred stock dividend         \$ 276,578         \$ 817,020				
Restricted cash         114,012         211,820           Net Cash Provided by Financing Activities         6,141,076         9,147,624           Net Increase In Cash and Cash Equivalents         930,521         2,961,693           Cash and Cash Equivalents, Beginning of Year         3,584,877         623,184           Cash and Cash Equivalents, End of Year         \$ 4,515,398         \$ 3,584,877           Supplemental Disclosure of Cash Flow Information:         S 5         \$ 2,433           Interest         \$ 5         \$ 2,433           Income taxes         \$ 5         \$ 3.584,877           Non-Cash Financing Activities:         \$ 5         \$ 3.584,877           Deferred financing Activities:         \$ 5         \$ 3.584,877           Warrant liability – reclassification to equity         \$ 5         \$ 817,020           Deemed dividend on convertible preferred stock due to beneficial conversion feature         \$ 581,300           Accumulated preferred stock dividend         \$ 276,578         \$ 80,578				
Net Cash Provided by Financing Activities         6,141,076         9,147,624           Net Increase In Cash and Cash Equivalents         930,521         2,961,693           Cash and Cash Equivalents, Beginning of Year         3,584,877         623,184           Cash and Cash Equivalents, End of Year         \$ 4,515,398         \$ 3,584,877           Supplemental Disclosure of Cash Flow Information:         Cash paid during the year:         Interest         \$ -         \$ 2,433           Income taxes         \$ -         \$ 2,433         \$ -         \$ -           Non-Cash Financing Activities:         \$ -         \$ 1,664,999         \$ 817,020           Deferred financing costs         \$ -         \$ 817,020         \$ 817,020           Deemed dividend on convertible preferred stock due to beneficial conversion feature         \$ -         \$ 581,300           Accumulated preferred stock dividend         \$ 276,578         \$ 80,578				
Net Increase In Cash and Cash Equivalents         930,521         2,961,693           Cash and Cash Equivalents, Beginning of Year         3,584,877         623,184           Cash and Cash Equivalents, End of Year         \$ 4,515,398         \$ 3,584,877           Supplemental Disclosure of Cash Flow Information:         Cash paid during the year:           Interest         \$ -         \$ 2,433           Income taxes         \$ -         \$ 2,433           Non-Cash Financing Activities:         \$ -         \$ 1,664,999           Warrant liability – reclassification to equity         \$ -         \$ 817,020           Deemed dividend on convertible preferred stock due to beneficial conversion feature         \$ -         \$ 581,300           Accumulated preferred stock dividend         \$ 276,578         \$ 80,578				
Cash and Cash Equivalents, Beginning of Year       3,584,877       623,184         Cash and Cash Equivalents, End of Year       \$ 4,515,398       3,584,877         Supplemental Disclosure of Cash Flow Information:         Cash paid during the year:       Interest       \$ 2,433         Income taxes       \$ 2,433         Non-Cash Financing Activities:       Deferred financing costs       \$ 1,664,999         Warrant liability – reclassification to equity       \$ 817,020         Deemed dividend on convertible preferred stock due to beneficial conversion feature       \$ 581,300         Accumulated preferred stock dividend       \$ 276,578       80,578	Net Cash Provided by Financing Activities	0,141,076 9,147,024		
Cash and Cash Equivalents, End of Year \$ 4,515,398 \$ 3,584,877  Supplemental Disclosure of Cash Flow Information: Cash paid during the year: Interest \$ - \$ 2,433 Income taxes \$ - \$ 1,664,999  Warrant liability – reclassification to equity Deemed dividend on convertible preferred stock due to beneficial conversion feature  Accumulated preferred stock dividend \$ 276,578 \$ 80,578	Net Increase In Cash and Cash Equivalents	930,521 2,961,693		
Supplemental Disclosure of Cash Flow Information:  Cash paid during the year:  Interest Income taxes  Solution - \$2,433 Income taxes  Non-Cash Financing Activities:  Deferred financing costs  Warrant liability – reclassification to equity Deemed dividend on convertible preferred stock due to beneficial conversion feature  Accumulated preferred stock dividend  Solution - \$1,664,999  Solution - \$1,664,999  Solution - \$1,000  Solu	Cash and Cash Equivalents, Beginning of Year	3,584,877 623,184		
Cash paid during the year:  Interest \$ - \$ 2,433 Income taxes \$ - \$ 2,433  Non-Cash Financing Activities:  Deferred financing costs \$ - \$ 1,664,999  Warrant liability – reclassification to equity Deemed dividend on convertible preferred stock due to beneficial conversion feature  Accumulated preferred stock dividend \$ 276,578 \$ 80,578	Cash and Cash Equivalents, End of Year	\$ 4,515,398 \$ 3,584,877		
Non-Cash Financing Activities:  Deferred financing costs  Warrant liability – reclassification to equity  Deemed dividend on convertible preferred stock due to beneficial conversion feature  Accumulated preferred stock dividend  \$ - \$ 581,300 \$ \$ 80,578				
Non-Cash Financing Activities:  Deferred financing costs  Warrant liability – reclassification to equity  Deemed dividend on convertible preferred stock due to beneficial conversion feature  Accumulated preferred stock dividend  \$ 276,578 \$ 80,578	Interest	<u>\$ -</u> <u>\$ 2,433</u>		
Deferred financing costs  Warrant liability – reclassification to equity  Deemed dividend on convertible preferred stock due to beneficial conversion feature  Accumulated preferred stock dividend  \$ - \$ 581,300 \$ \$ 276,578 \$ 80,578	Income taxes	<u>\$ -</u> <u>\$ -</u>		
Warrant liability – reclassification to equity  Deemed dividend on convertible preferred stock due to beneficial conversion feature  \$ - \$817,020  \$ 581,300  Accumulated preferred stock dividend  \$ 276,578 \$ 80,578				
Deemed dividend on convertible preferred stock due to beneficial conversion feature  \$ - \$ 581,300  Accumulated preferred stock dividend \$ 276,578 \$ 80,578	Deferred financing costs			
Accumulated preferred stock dividend         \$ 581,300           \$ 276,578         \$ 80,578	Warrant liability – reclassification to equity	\$ <u>-</u> \$ 817,020		
Accumulated preferred stock dividend \$ 276,578 \$ 80,578	Deemed dividend on convertible preferred stock due to beneficial conversion feature	ф <u>Б</u>		
Decrease in accrued liabilities - stock-based compensation \$\frac{\\$121,720}{\}\$\$	Accumulated preferred stock dividend			
	Decrease in accrued liabilities - stock-based compensation	\$ 121,720 \$ <u> </u>		



Source: Lightbridge Corporation